Composite Lymphoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma (NCT02541565) | University of Washington | 2015-11-24 |
Track Composite Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.